Editorial: Commercialization and industrialization of pharmacology of infectious diseases: 2022

• Yanqin Huang,
• Yanqin Huang,
• Sue C. Nang,
• Yu-Wei Lin,
• Yu-Wei Lin,
• Yu-Wei Lin,
• Yu-Wei Lin,
• Yu-Wei Lin,
• Fekade Sime

Affiliations

Yanqin Huang

Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, United States

Yanqin Huang

Harvard Medical School, Boston, MA, United States

Sue C. Nang

Department of Microbiology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia

Yu-Wei Lin

Department of Microbiology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia

Yu-Wei Lin

Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia

Yu-Wei Lin

Malaya Translational and Clinical Pharmacometrics Group, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia

Yu-Wei Lin

Department of Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia

Yu-Wei Lin

Certara Drug Development Solutions, Certara, Radnor, PA, United States

Fekade Sime

Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia